Trastuzumab is the only approved treatment for HER2-positive gastric cancer (von Arx et al., 2023), and its resistance is linked to hexokinase 2 (HK2)-controlled high-glucose enzymatic activity. The gene discussed is HK2; the disease is gastric cancer.